Startups, Venture

How to build a biotech unicorn: Get the star team in place, attract deep-pocket VCs, paint a big picture and raise up to $1B

/>

by — on
Updated:

When Steve Harr sketched out the barebones essentials of his strategic plan for the new cell therapy company Sana Biotechnology a few days ago, he was careful to steer clear of detailing his exact plans for his first big raise for the biotech. But some numbers have been starting to appear — and not surprisingly they paint a picture of a young unicorn still at foal stage.

In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)

← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 37,400+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 37,400+ biopharma pros who read Endpoints News by email every day.

Free Subscription
Biotech Investment Analyst
SV Health Investors Boston, MA
Director, Program Management
Contrafect Corporation New York, NY
Director, Translational Sciences
Cadent Therapeutics Cambridge, MA
Visit Endpoints Careers ->